Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
Blue Sky Uranium Acquires Key Subsurface Data for Corcovo Uranium Project, Mendoza Province, Argentina
Group Eleven Drills Best Hole Yet at Ballywire: 39.7m of 9.5% Zn+Pb, 131 g/t Ag and 0.27% Cu, incl. 5.6m of 16.6% Zn+Pb, 370 g/t Ag and 0.86% Cu
